Clinical Trial Update: GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial of durvalumab plus tremelimumab with paclitaxel for metastatic gastric cancer completed Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• PACLITAXEL (PACLITAXEL)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Asan Medical Center | Conditions: Metastatic Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED